Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Income from Continuing Operations (2016 - 2025)

United Therapeutics' Income from Continuing Operations history spans 17 years, with the latest figure at 364300000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 20.91% year-over-year to 364300000.0; the TTM value through Dec 2025 reached 1334700000.0, up 11.68%, while the annual FY2025 figure was 1334700000.0, 11.68% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 364300000.0 at United Therapeutics, up from 338700000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 364300000.0 in Q4 2025 and bottomed at 28300000.0 in Q1 2021.
  • The 5-year median for Income from Continuing Operations is 250050000.0 (2023), against an average of 235885000.0.
  • The largest annual shift saw Income from Continuing Operations crashed 79.45% in 2021 before it skyrocketed 747.7% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 112200000.0 in 2021, then increased by 17.74% to 132100000.0 in 2022, then skyrocketed by 64.35% to 217100000.0 in 2023, then skyrocketed by 38.78% to 301300000.0 in 2024, then grew by 20.91% to 364300000.0 in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Income from Continuing Operations are 364300000.0 (Q4 2025), 338700000.0 (Q3 2025), and 309500000.0 (Q2 2025).